Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High Dose Ascorbate + Azacitidine in MDS
NCT07283900Phase 2Suspended
- Start
- Mar 2026
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ascorbic acid in myelodysplastic syndrome (MDS). Started Mar 2026; status: suspended.
02
Drugs
ascorbic acid
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT07283900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07283900.